Nuveen
CSTL icon

Nuveen’s Castle Biosciences CSTL Stock Holding History

Nuveen’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.53M Sell
231,726
-290,401
-56% -$6.47M ﹤0.01% 2041
2026
Q1 		$12.8M Sell
522,127
-2,554
-0.5% -$83.7K ﹤0.01% 1411
2025
Q4 		$20.4M Sell
524,681
-432,400
-45% -$13.9M 0.01% 1135
2025
Q3 		$21.8M Sell
957,081
-116,026
-11% -$2.36M 0.01% 1098
2025
Q2 		$21.9M Buy
1,073,107
+401,296
+60% +$7.43M 0.01% 1039
2025
Q1 		$11.9M Buy
671,811
+206,285
+44% +$5.11M ﹤0.01% 1447
2024
Q4 		$12.4M Sell
465,526
-77,067
-14% -$2.35M ﹤0.01% 1483
2024
Q3 		$15.5M Buy
542,593
+256,082
+89% +$6.52M ﹤0.01% 1349
2024
Q2 		$6.24M Buy
286,511
+96,883
+51% +$2.16M ﹤0.01% 1839
2024
Q1 		$4.2M Buy
189,628
+7,154
+4% +$156K ﹤0.01% 2078
2023
Q4 		$3.94M Buy
182,474
+6,190
+4% +$109K ﹤0.01% 2095
2023
Q3 		$2.98M Sell
176,284
-240,130
-58% -$4.2M ﹤0.01% 2127
2023
Q2 		$5.71M Buy
416,414
+10,656
+3% +$216K ﹤0.01% 1840
2023
Q1 		$9.22M Buy
405,758
+103,109
+34% +$2.52M ﹤0.01% 1535
2022
Q4 		$7.12M Buy
302,649
+191,974
+173% +$4.45M ﹤0.01% 1709
2022
Q3 		$2.89M Sell
110,675
-1,980
-2% -$55.5K ﹤0.01% 2196
2022
Q2 		$2.47M Buy
112,655
+40,888
+57% +$950K ﹤0.01% 2330
2022
Q1 		$3.13M Buy
71,767
+776
+1% +$32.1K ﹤0.01% 2294
2021
Q4 		$2.76M Sell
70,991
-5,521
-7% -$288K ﹤0.01% 2405
2021
Q3 		$5.92M Sell
76,512
-5,474
-7% -$385K ﹤0.01% 2115
2021
Q2 		$6.01M Buy
81,986
+30,342
+59% +$2M ﹤0.01% 2150
2021
Q1 		$3.54M Sell
51,644
-29,149
-36% -$2.19M ﹤0.01% 2339
2020
Q4 		$5.42M Sell
80,793
-3,509
-4% -$190K ﹤0.01% 2030
2020
Q3 		$4.34M Buy
84,302
+29,462
+54% +$1.31M ﹤0.01% 1990
2020
Q2 		$2.07M Sell
54,840
-9,625
-15% -$329K ﹤0.01% 2328
2020
Q1 		$1.92M Sell
64,465
-50,272
-44% -$1.52M ﹤0.01% 2211
2019
Q4 		$3.94M Sell
114,737
-50,569
-31% -$1.24M ﹤0.01% 2114
2019
Q3 		$2.99M Buy
+165,306
New +$3.66M ﹤0.01% 2213

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's CSTL Position: Q2 2026 in Review

Nuveen reduced its Castle Biosciences (CSTL) stake by 56% in Q2 2026, selling an estimated $6.47M and leaving 231,726 shares worth $5.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2041.

Nuveen first reported a position in CSTL in Q3 2019 and has held it in 28 quarters since. The position peaked at $21.9M in Q2 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Nuveen held 231,726 shares of Castle Biosciences worth $5.53M as of Q2 2026.
  • Nuveen sold 290,401 Castle Biosciences shares in Q2 2026, an estimated $6.47M.
  • Castle Biosciences made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2041 holding.
  • Nuveen first reported a position in Castle Biosciences in Q3 2019 and has held it in 28 quarters since.
  • Nuveen's Castle Biosciences position peaked at $21.9M in Q2 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.